A closer look at LATE: a Case Report on a subtly evolving neurodegenerative disorder.

Neurol SciOct 26, 2026 (epub)
Case ReportNeurologyNuclear MedicineOpen access

Maria Luisa Di Giesi, Francesco Motolese, Davide Norata et al.

✦ AI-curated · Sources linked

Case in brief

A 71-year-old presented with isolated episodic memory impairment, preserved global cognition, and intact daily function. Initial cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarkers were negative, and 18F-FDG PET showed mild bilateral medial temporal hypometabolism. As memory declined over subsequent years, MRI showed bilateral medial temporal atrophy. Repeat CSF testing remained negative for AD biomarkers, with markedly elevated neurofilament light chain levels. PET showed worsening bilateral medial temporal hypometabolism but preserved inferolateral temporal metabolism. The slowly progressive, medial temporal-predominant amnestic syndrome supported a diagnosis of limbic-predominant age-related TDP-43 encephalopathy (LATE).

What made this case unusual

Despite an amnestic presentation resembling AD, inferolateral temporal metabolism—typically reduced in AD—remained preserved as medial temporal hypometabolism progressed.

Diagnostic / clinical pearl

In an older adult with a hippocampal-type amnestic syndrome, persistently negative AD biomarkers alongside medial temporal-predominant neurodegeneration should prompt consideration of LATE.

Why it matters

Recognizing this diagnostic possibility may help avoid ineffective anti-amyloid therapy and refine clinical trial selection.

Source

Published in Neurol Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.